Spyre Therapeutics (SYRE) News Today $29.20 -2.07 (-6.62%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Robert W. Baird Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) StockNovember 17 at 4:13 AM | americanbankingnews.comBrokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $46.43November 16 at 6:03 AM | americanbankingnews.comResearch Analysts Set Expectations for SYRE Q1 EarningsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Analysts at Wedbush lowered their Q1 2025 earnings per share (EPS) estimates for Spyre Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.86) per shNovember 15 at 7:52 AM | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)November 14 at 1:40 AM | markets.businessinsider.comSpyre Therapeutics price target raised to $65 from $50 at BairdNovember 13, 2024 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)November 13, 2024 | markets.businessinsider.comRobert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock PriceRobert W. Baird raised their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday.November 13, 2024 | marketbeat.comQ1 Earnings Forecast for SYRE Issued By WedbushNovember 13, 2024 | americanbankingnews.comSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance DosingNovember 12, 2024 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024November 11, 2024 | prnewswire.comEquities Analysts Offer Predictions for SYRE Q1 EarningsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Spyre Therapeutics in a report issued on Friday, November 8th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.84) per shareNovember 11, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned a consensus recommendation of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating. The average twelve-month pricNovember 9, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)Wedbush reissued an "outperform" rating and set a $45.00 price objective on shares of Spyre Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comSpyre Therapeutics: Q3 Earnings SnapshotNovember 7, 2024 | sfgate.comSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.com292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Emerald Advisers LLCEmerald Advisers LLC acquired a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 292,569 shares of the company's stock, valued at appNovember 3, 2024 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsNovember 1, 2024 | prnewswire.comSpyre Therapeutics to Participate in Upcoming November Investor ConferencesOctober 30, 2024 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Director Jeffrey W. Albers Sells 300 SharesOctober 29, 2024 | insidertrades.comJeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) StockSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) Director Jeffrey W. Albers sold 300 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $36.43, for a total value of $10,929.00. Following the completion of the transaction, the director now directly owns 34,060 shares in the company, valued at $1,240,805.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.October 28, 2024 | marketbeat.comGuggenheim Raises Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00Guggenheim increased their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Friday.October 25, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?October 25, 2024 | marketbeat.comAssenagon Asset Management S.A. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Assenagon Asset Management S.A. purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,142,768 shares of the company's stock, valued at approximately $33,609,000.October 25, 2024 | marketbeat.comBuy Rating Justified for Spyre Therapeutics Due to Accelerated Drug Development and Promising Preclinical DataOctober 18, 2024 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5% - Here's What HappenedSpyre Therapeutics (NASDAQ:SYRE) Trading 4.5% Higher - Here's What HappenedOctober 17, 2024 | marketbeat.comWells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)October 15, 2024 | markets.businessinsider.comSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and CombinationsOctober 14, 2024 | prnewswire.comThe Manufacturers Life Insurance Company Acquires New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE)The Manufacturers Life Insurance Company bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,782 shares of the company's stock, valued atOctober 14, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 3.5% - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Trading Down 3.5% - What's Next?October 9, 2024 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsOctober 4, 2024 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Trading 2.5% Higher Spyre Therapeutics (NASDAQ:SYRE) Trading Up 2.5%October 3, 2024 | marketbeat.comSpyre Therapeutics Appoints Sheldon Sloan As New Chief Medical OfficerOctober 1, 2024 | markets.businessinsider.comSpyre: Extended Half-Life Tech To Become Differentiating Factor For IBD TargetingOctober 1, 2024 | seekingalpha.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.6%Spyre Therapeutics (NASDAQ:SYRE) Trading Down 7.6%October 1, 2024 | marketbeat.comSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical OfficerOctober 1, 2024 | prnewswire.comPerceptive Advisors LLC Increases Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Perceptive Advisors LLC grew its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 18.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,031,018 shares of the company'September 30, 2024 | marketbeat.com687,080 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Driehaus Capital Management LLCDriehaus Capital Management LLC acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 687,080 shaSeptember 29, 2024 | marketbeat.comEnsign Peak Advisors Inc Invests $1.94 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Ensign Peak Advisors Inc acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 82,475 shares of the company's stock, valued at approximaSeptember 28, 2024 | marketbeat.comArmistice Capital LLC Invests $3.20 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Armistice Capital LLC bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 136,000 shares of the company's stock, valSeptember 27, 2024 | marketbeat.com452,040 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Darwin Global Management Ltd.Darwin Global Management Ltd. bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 452,040 shares of the company's stock, valued at approximately $10,266,00September 26, 2024 | marketbeat.comAffinity Asset Advisors LLC Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Affinity Asset Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 513,420 shares of the company's stock, valued at approximately $12,071,0September 25, 2024 | marketbeat.comGreat Point Partners LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Great Point Partners LLC bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 134,612 shares of the company's stoSeptember 24, 2024 | marketbeat.com100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLCIntegral Health Asset Management LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 100,000 shares of the company's stock, valued at apprSeptember 23, 2024 | marketbeat.com51,896 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Rhumbline AdvisersRhumbline Advisers purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,896 shares of the company's stock, valued at approximately $1,220,000. Rhumbline Advisers oSeptember 22, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts thaSeptember 20, 2024 | marketbeat.comFairmount Funds Management LLC Expands Stake in Viridian Therapeutics IncSeptember 18, 2024 | finance.yahoo.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Spyre Therapeutics (NASDAQ:SYRE) Shares Down 5%September 16, 2024 | marketbeat.comBank of New York Mellon Corp Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Bank of New York Mellon Corp bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 117,686 shares of the company's stock, valued at approximately $2,767,000. Bank of NewSeptember 16, 2024 | marketbeat.comTD Asset Management Inc Takes $827,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)TD Asset Management Inc acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 35,168 shares of the company's stock, valuedSeptember 15, 2024 | marketbeat.com464,435 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by First Turn Management LLCFirst Turn Management LLC acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 464,435 shares of the company's stock, valued at approximately $10,919,00September 13, 2024 | marketbeat.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.510.55▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼172▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ELAN News Today VKTX News Today CYTK News Today BPMC News Today LNTH News Today NUVL News Today RNA News Today ACLX News Today KRYS News Today ADMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts